1-[(3,4-dimethoxyphenyl)methyl]-2-[3-({5-[(3-{1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propanoyl)oxy]pentyl}oxy)-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium

• ChemBase编号: 613
• 分子式: C53H72N2O12++
• 平均质量: 929.14498
• 单一同位素质量: 928.50852575
• SMILES: O(c1cc2C([N+](CCc2cc1OC)(CCC(=O)OCCCCCOC(=O)CC[N+]1(C(c2c(CC1)cc(OC)c(OC)c2)Cc1cc(OC)c(OC)cc1)C)C)Cc1cc(OC)c(OC)cc1)C
• Canonical SMILES: COc1cc2c(cc1OC)CC[N+](C2Cc1ccc(c(c1)OC)OC)(C)CCC(=O)OCCCCCOC(=O)CC[N+]1(C)CCc2c(C1Cc1ccc(c(c1)OC)OC)cc(c(c2)OC)OC
• InChI: InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2
• InChIKey: YXSLJKQTIDHPOT-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 1-[(3,4-dimethoxyphenyl)methyl]-2-[3-({5-[(3-{1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propanoyl)oxy]pentyl}oxy)-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium
• IUPAC传统名: atracurium
• 别名: Atracurium; Atracurium besilate

登记号

• CAS号: 64228-79-1
• PubChem SID: 160964076; 46504689
• PubChem CID: 47319
• CHEBI ID: 2914
• ATC码: M03AC04
• CHEMBL: 1360
• Chemspider ID: 43067
• DrugBank ID: DB00732
• 美国药典/FDA物质标识码: 40AX66P76P
• 维基百科标题: Atracurium_besilate

理论计算性质

JChem

• Acid pKa: 19.016506
• 质子受体: 10
• 质子供体: 0
• LogD (pH = 5.5): -0.95903206
• LogD (pH = 7.4): -0.95903206
• Log P: -0.95903206
• 摩尔折射率: 280.6772 cm^3
• 极化性: 100.60693 Å^3
• 极化表面积: 126.44 Å^2
• 可自由旋转的化学键: 26
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: 3.41
• LOG S: -7.63
• 溶解度: 2.32e-05 g/l

分子性质

理化性质

• 溶解度: Miscible

药理学性质

• 给药途径: IV
• 生物利用度: 100% (IV)
• 半衰期: 17–21 minutes
• 代谢: Hofmann elimination (retro-Michael addition) and ester hydrolysis by nonspecific esterases
• 蛋白结合率: 82%
• 法定药品分级: Worldwide: Prescription only medicine

详细说明

DrugBank - DB00732

• Drug Groups: approved
• Description: A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents. [PubChem]
• Indication: For use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
• Pharmacology: Atracurium is a nondepolarizing skeletal muscle relaxant. Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. The duration of neuromuscular block produced by Atracurium is approximately one third to one half the duration of block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of Atracurium. Repeated administration of maintenance doses of Atracurium has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.
• Toxicity: Excessive doses can be expected to produce enhanced pharmacological effects. Overdosage may increase the risk of histamine release and cardiovascular effects, especially hypotension.
• Affected Organisms: Humans and other mammals
• Half Life: The elimination half-life is approximately 20 minutes.
• External Links: Wikipedia; RxList